NASHVILLE, Jan. 9, 2023 — Monogram Health, a value-based specialist provider of in-home evidence-based treatment and benefit management services for patients with polychronic illnesses such as chronic kidney disease and end-stage renal disease, said today that it has closed on USD 375 million in fresh capital.
Leading strategic investors CVS Health, Humana, Cigna Ventures, Memorial Hermann Health System, and SCAN participated in this milestone growth funding round, as did new and existing financial investors such as TPG Capital, Frist Cressey Ventures, Heritage Group, Pura Vida Investments, and Norwest Venture Partners.
Monogram will utilize the funds to support the company’s novel in-home renal and polychronic care delivery strategy and its technology-driven variety of evidence-based clinical services, such as complicated case and illness management, utilization management, and pharmaceutical therapy management. This novel care paradigm improves how kidney disease and concomitant metabolic diseases are treated. It has been demonstrated to significantly improve patient outcomes and quality of life while lowering medical costs throughout the healthcare continuum, enhancing access and affordability for all.
Todd Sisitsky, TPG President and Co-Managing Partner of TPG Capital:
“Monogram is delivering a new, integrated approach to in-home care delivery that expands access and engagement, cuts costs, and drives better results for patients with chronic kidney disease. We’re excited to continue working with Mike and the Monogram team and a world-class syndicate of strategic investors.”
CEO and Co-Founder of Monogram Health, Mike Uchrin :
“At Monogram Health, we use our patented, evidence-based procedures and technology to actively treat patients’ kidney disease and a wide spectrum of acute and chronic illnesses. Everything we do aims to improve access to health care and health outcomes for polychronic patients by addressing their specific requirements in their homes, altering the patient experience, particularly for those who have historically been neglected.”
More about the company:
Monogram Health is a leading value-based specialist provider of in-home evidence-based treatment and benefit management services to patients suffering from polychronic illnesses such as chronic kidney disease and end-stage renal disease. To change the way health care is delivered for those with polychronic conditions, the company uses an innovative in-home delivery model and a technology-driven array of evidence-based clinical services, such as complex case and disease management, utilization management, and medication therapy management. This unique treatment paradigm has been proven to enhance patient outcomes and quality of life while lowering medical expenditures across the healthcare continuum.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
